Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New DrugEsperion Therapeutics' proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.

More From CBS Detroit

Best Christmas Light Displays
Best Holiday Drink Ideas
Top Hidden Destinations

Watch & Listen